Abstract
We conducted descriptive longitudinal follow-up and uncontrolled studiesperformed on 185 subjects who received 2 doses of 15µg IVACFLU-A / H5N1vaccine 21 days apart to determine persistent of antibody-H5N1 and someEpidemiological characteristics involved, the results showed that: 18 monthsafter IVACFLU-A/H5N1 vaccination, the rate of antibody protection (titre ≥1/40)still reached 61.6%; GMTs of the injection group reached 49.2. No staticallydifferences on age, gender and epidemiological characteristics related persistent ofanti-H5N1 antibody after vaccination. The research is still ongoing until 36months after vaccination.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: TẠP CHÍ PHÒNG CHỐNG BỆNH SỐT RÉT VÀ CÁC BỆNH KÝ SINH TRÙNG
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
